Glaukos Reports $211 Million in Quarterly Revenue
The Aliso Viejo-based ophthalmic medical technology company announced its financial results for the third quarter of 2026.
Updated on Oct. 28, 2026 in Public Companies
Live Poll
Do you believe current corporate earnings growth in your area suggests a healthy local economy?
Glaukos Corporation recorded $211 million in revenue during the third quarter of 2026. The company also reported a net income of $2 million, or 3 cents per share.
Why it matters
The company's earnings report provides transparency into its financial health and operational performance for the 2026 fiscal year. Investors and stakeholders rely on these figures to gauge the growth trajectory of the Aliso Viejo business.
Glaukos reported quarterly revenue of $211 million and a net income of $2 million. The company achieved an adjusted earnings per share of 47 cents, a figure that excludes non-recurring costs.
The players
Glaukos Corporation
Glaukos Corporation is a medical technology company based in Aliso Viejo that specializes in developing treatments for ophthalmic conditions.
The details
The medical technology firm headquartered in Aliso Viejo confirmed that its quarterly net income reached $2 million. Additionally, management issued full-year revenue projections expected to fall between $775 million and $785 million.
Timeline
The financial results cover the third quarter of 2026.
Market Landscape
This earnings report adheres to the SEC's Form 10-Q disclosure requirements regarding standard quarterly financial updates provided to shareholders. The release follows the industry-standard financial reporting cycle mandated for public companies operating in the medical device sector.
The reported figures offer insight into the current financial standing of a major Aliso Viejo employer for residents and investors tracking the company. These results typically influence market sentiment and long-term investment strategies related to the firm's stock.
The takeaway
Maintaining steady revenue growth remains a key performance indicator for firms within the competitive medical technology space. Investors should continue to monitor future quarterly filings to assess how the company's performance aligns with its annual guidance.
Further reading
For more information on the local business environment, visit Public Companies.
Live Poll
Do you believe current corporate earnings growth in your area suggests a healthy local economy?
